AbbVie announced results from the Phase III MIRASOL trial evaluating Elahere, an antibody-drug conjugate, for platinum-resistant ovarian cancer. The study showed improved progression-free survival, response rate, and overall survival compared to chemotherapy, offering hope for patients with limited options.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing